Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Equips Plants for Malaria Drug That Could Help Fight Covid-19 -Handelsblatt

share with twitter share with LinkedIn share with facebook
share via e-mail
04/02/2020 | 04:54am EDT

--Bayer's Chief Executive Werner Baumann said the pharmaceutical giant is expanding production capacities for its malaria drug Resochin after indications that the drug could slow down the spread of the novel coronavirus and therefore lead to a milder course of the disease, Handelsblatt reports.

--In an interview with the German business newspaper, Mr. Baumann said further clinical studies would be necessary to clarify the risk-benefit ratio of the drug but the company's production plants in Europe would be adjusted to produce it.

--So far, the drug is manufactured only at one plant in Pakistan, Handelsblatt reports.

 

Full story (in German): https://bit.ly/39yPrvK

 

Write to Barcelona editors at barcelonaeditors@dowjones.com

 

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -3.56% 60.72 Delayed Quote.-16.60%
THE LEAD CO., INC. -2.37% 412 End-of-day quote.5.64%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
05/29BAYER AG : Gets a Buy rating from Bernstein
MD
05/29BAYER : Efficacy of Vitrakvi™ (larotrectinib) further established with con..
PU
05/29BAYER : Elanco proposes divestments of some animal health products in Bayer acqu..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/28FCA Gives Guidance For Common PM(NOC) Trials Involving Multiple Actions
AQ
05/27German chemicals industry sees coronavirus hitting 2020 revenue
RE
05/27Rising Swiss rivalry as Roche and Novartis target same diseases
RE
05/26GLOBAL MARKETS LIVE: Labs step up efforts to find coronavirus vaccine
05/26BAYER AG : Deutsche Bank reaffirms its Buy rating
MD
05/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials
Sales 2020 44 246 M 49 144 M 49 144 M
Net income 2020 4 544 M 5 047 M 5 047 M
Net Debt 2020 29 621 M 32 899 M 32 899 M
P/E ratio 2020 13,9x
Yield 2020 4,81%
Capitalization 59 653 M 66 318 M 66 256 M
EV / Sales 2019
EV / Sales 2020 2,02x
Nbr of Employees 102 201
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,44 €
Last Close Price 60,72 €
Spread / Highest target 81,2%
Spread / Average Target 32,5%
Spread / Lowest Target -55,6%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Paul Achleitner Member-Supervisory Board
Reiner Hoffmann Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-16.60%66 318
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274